Original Research Article

Clinico- haematological Profile of Sickle Cell Disease and Sickle Cell Beta-Thalassaemia in the State of Odisha

Authors
Dharma Niranjan Mishra¹, Manoj Kumar Naik², Rabindra Kumar Jena³

¹Assistant Professor Department of Anatomy S. C. B. Medical College Cuttack 753007, Orissa, India
²Assistant Professor Department of Anatomy M.K.C.G Medical College Berhampur 760004, Orissa, India
³Professor and Head Dept of clinical Haematology S. C. B. Medical College Cuttack 753007, Orissa, India

Abstract

Background: Hemoglobinopathy is a group of inherited disorders characterized by structural variations of the hemoglobin molecule. Sickle cell disease, beta thalassemia and sickle beta thalassemia constitute the major genetic blood disorders in Odisha. The aim of this study was to determine the clinico-haematological patterns of patients with sickle cell haemoglobinopathies.

Methods: Blood samples are collected from 88 subjects diagnosed as sickle cell disease and sickle β+ thalassemia after taking informed consent as well as appropriate ethical clearance. Screening is done by sickling test and capillary electrophoresis.

Results: Out of 88 patients 43 patients (48.9%) are Sickle Cell Disease (28 males and 15 females) and 45 patients (51.1%) are S/ß Thalassaemia (37 males and 08 females) included in the present comparative study. Results are statistically analysed and tested using student’s t-test for significance. Since there is no statistically significant sex differences observed for different haematological indices in the studied diagnostic categories, their mean values are pooled together for comparison purposes. Statistically significant higher mean values were observed in sickle beta thalassemia patients i.e. HbA mean 3.69±2.94 P value <0.0027, HbA2 mean 4.12 P value <0.017 than in the sickle cell Disease. In Sickle Cell Disease the mean height is 145.69±31.08 P value <0.001, serum ferritin level 737.8±772.6 P value <0.0003 and HbS levels72.8±8.03 P value <0.01, which is significantly higher than Sickle Cell Beta Thalassemia. Hydroxyurea was administered orally at doses between 10 and 20 mg/kg per day. There are overall increases in HbF in most of the cases with reductions in the frequency of recurrent blood transfusion, vasoocclusive crisis and avascular necrosis.

Conclusion: Molecular diagnosis of Hb D, HbE or Hb S gene is required along with characterization of β-thalassemia mutations in this region.

Abbreviations: HbS –Sickle cell Haemoglobin, HbF –foetal Haemoglobin and S/ßThalassaemia: Sickle beta Thalassemia

Keywords: Hemoglobinopathy, sickle cell disease, S/ßThalassaemia,

Introduction

The combination of the sickle cell mutation and beta-thalassemia (β-Thal) mutation gives rise to a compound heterozygous condition known as Hb S/β thalassemia (Hb S/β-Thal), which was first described in 1944 by Silvestroni and Bianco (¹). Sickle β thalassemia is a major haemoglobin disorder responsible for most of the symptoms and
complications of sickle cell disease. Patient’s heterozygous Sickle cell Haemoglobin (HbS) and beta Thalassemia (β-Thal) may suffer sickle cell disease but their symptoms are less severe than the homozygous sickle cell disease, which is known as Sickle cell beta thalassemia (Hb S/β-Thal) (2). Hb S/β-Thal is classified according to severity as sickle cell β⁺ thalassemia in which β globin production is zero, Sickle cell β⁺⁺ thalassemia where β globin is produced is less than normal and the milder form is designated as Sickle cell β⁺⁺⁺ thalassemia with high Hb A (20-30%). Increased Hb A2 is the diagnosed feature of β thalassemia is found both in β⁺ & β⁺⁺ thalassemia (2). The symptoms of Sickle cell disease and Sickle cell β⁺⁺ thalassemia is almost similar involving irreversible sickle cell, severe anaemia and frequent vaso occlusive crisis(3). In HbS/β-thalassemia, the β-thalassaemia gene interacts with the Hbs-gene to increase the level of HbF (usually>15%) and HbS from above 50% to a level near that observed in sickle cell disease (HbSS) individuals (5). Relative higher level of HbF in this double heterozygous condition may be beneficial by decreasing HbS polymerization while adding a new detrimental effect by aggravating the mild haemolytic components of HbS gene. The net phenotypic expression of the interaction of two genes is remarkably variable i.e. completely asymptomatic condition at one end while at the other end of the spectrum, the severity can be that of SCD or β⁺-Thalassaemia (6,7). Changes in haematological parameters include microcytic red cell, target cell, 60-90%of HbS, 0-30% of HbA, 1-20% of HbF (8). The type of β-thalassaemia gene that is co-inherited with HbS gene may partly explain such variations which need to be corroborated by further study. Moreover, the high incidence of iron deficiency and α-thalassaemia gene in our population may alter the picture significantly which is relevant to their management. Few published study regarding vascular phenotypes of SCD (HbSS) and genotype-phenotype expression of HbS –β-thalassaemia are available from Orissa as well as from the whole country. Orissa is a state where there is higher percentage of HbF in SCD (HbSS) and high prevalence of both HbS and β-thalassaemia genes and thus HbS-β-thalassaemia. The study of these haemoglobinopathies has a tremendous importance in our state.

Material & Method
Study Design: Cohort Study (Prospective Observational study) with asking research questionnaire developed for this purpose,
Study Location:- This study is based on 43 cases sickle cell disease and 45 cases of sickle beta thalassaemia selected from the Out Patient Department (OPD) cases in the clinical haematology, S.C.B. Medical College Hospital, Cuttack from 20013 to 2016. Their family history, name, age, sex, caste, native place, pedigree chart and clinical sign symptoms were rerecorded after taking written consent. About 3-4 ml IV blood samples were collected using EDTA as anti coagulant by disposable syringe from each patient. Clinical sign and symptoms related to haemoglobinopathy and laboratory investigations were done by automated blood cell counter and haemoglobin electrophoresis. Sickling test was done by sodium matabisulphite solution as a reducing agent for the presence of sickle cell haemoglobin.

Inclusion Criteria: All patients who diagnosed or suspecting to have a sickle cell haemoglobinopathies and confirmed by positive sickling test.
Exclusion criteria: Healthy people who suspected to have sickle cell haemoglobinopathies with negative sickling test.

Ethical issues
This study confirms to the ethical principles of medical research developed by the World Medical Association Declaration of Helsinki. Ethical clearance was given by the Instititual Ethics Committee S.C.B Medical College Cuttack, 753007 [Orissa] IEC/IRB No:94/24.02.2011.

Data Analysis
All data obtained with questionnaire and biochemical analysis were analyzed using the
Graph Pad program for Windows (Graph Pad Software). Statistical significance was accepted when P value is \( \leq 0.05 \)

**Results**

There were in all 88 cases, out of which 43 (28 males and 15 females) were sickle cell Disease and 45 cases (37 males and 08 females) were sickle cell β+ thalassemia included in the present comparative study. We observed 28 male (65.11%) and 15 female (34.88%) patients in Sickle Cell Disease, M:F was being 2:1 approximately. There were 45 cases of Sickle beta Thalassemia with 37 male and 08 female the M: F ratio was being 4.6:1.

| Table No 1: | Sex Distribution of Sickle Cell Disease and Sickle B+ Thalassemia |
|-------------|---------------------------------------------------------------|
|             | SCD: sickle cell disease, SBTβ+: sickle beta+ thalassemia    |
| Disease     | SCD                         | SBTβ+                      |
| Sex         | Male | Female | Total | Male | Female | Total |
| Number      | 28   | 15     | 43    | 37   | 08     | 45    |
| Percentage  | 65.11% | 34.89% | 82.22% | 17.78% |

**Table No 2: Mean Age and Standard Deviation**

| Disorder | Minimum | Maximum | Median | Total | Mean ±S/D |
|----------|---------|---------|--------|-------|-----------|
| SCD      | 02      | 62      | 18     | 43    | 20.14±13.16 |
| SBT      | 04      | 34      | 17     | 45    | 17.16±8.7   |

Table No 2: Out of 45 cases of Sickle Beta Thalassemia between the ages of 4 to 34 years, the median age was being 17 years and 43 cases of Sickle Cell Disease between the ages 02 to 62 years, the median age was being and 18 years. The mean age and Standard Deviation was being 17.16± 8.7 and 20.14±13.16 in both the observed groups. The P value (<0.2), which was statically insignificant. There were 41 cases (91%) has been seen below 30 years of age in Sickle beta Thalassemia and 37(86%) in Sickle Cell Disease.

**Table No:3 Clinical Finding**

R-VOC: recurrent vaso occlusive crisis, AVN: avascular necrosis and BT: blood transfusion

| Findings     | Sickle Cell Disease (n=43) | Sickle B+Thalassemia (n=45) |
|--------------|---------------------------|-----------------------------|
| Spleen       | 20                        | 23                          |
| Liver        | 15                        | 10                          |
| R-VOC        | 29                        | 14                          |
| B T Required | 14.45±1.84(n=22)           | 5.44±1.97(n=18)             |
| AVN          | 01                        | 00                          |
| Hypertension | 01                        | 00                          |
| Cholelithias | 00                        | 01                          |

At the time of diagnosis Splenomegally was invariably present 20 out of 43 cases (64.44) and 23 out of 45 cases in both the phenotypes. Splenic enlargement was found 2-4 cms below the left costal margin in an average and only in two cases >12cm were observed. Hepatomegally was also observed in 15 and 10 cases in the present study. Out of 43 cases of SCD recurrent blood transfusion was required in 22 cases (14.45± 1.84) and 18 cases (5.44±1.97) in SB+ Thalassemia having P value< 0.001 which is statistically very significant. Avascular necrosis, Hypertension and Cholelithiasis were showed insignificant association in our study. Table No 3
Table No 4: Sickle Cell Disease (n=43) Mean value of hematological indices.

|                          | Mean  | S/D  | P Value | S/E |
|--------------------------|-------|------|---------|-----|
| **Age yrs**              | 20.14 | 13.16| <0.0001 | 2.0 |
| **Height**               | 145.69| 31.08| <0.0001 | 4.74|
| **Weight**               | 42.14 | 14.22| <0.0001 | 2.17|
| **Hb%**                  | 9.64  | 1.43 | <0.0001 | 0.22|
| **TLC K**                | 9372.1| 1157.3|<0.0001| 240.5|
| **TPC L**                | 186.11| 17.78|<0.0001| 2.7 |
| **FERRITIN ng**          | 737.8 | 772.6|<0.0001| 117.8|
| **MCV fl**               | 62.11 | 2.11 |<0.0001| 0.322|
| **MCH pg**               | 19.02 | 2.07 |<0.0001| 0.316|
| **MCHC**                 | 26.91 | 1.42 |<0.0001| 0.217|
| **HbA%**                 | 2.27  | 0.7 |<0.0001| 0.122|
| **HbF%**                 | 19.8  | 8.7 |<0.0001| 1.33 |
| **HbA2%**                | 3.40  | 1.71 |<0.0001| 0.261|
| **HbS%**                 | 72.8  | 8.03 |<0.0001| 1.23 |

Table No 4: The mean height in centimeters is 145.69 cms (±31.08) range 53 to 170 centimeters and weight in kilograms is 42.14 kg (±14.22) range 10 to 60 kilograms which indicates growth retardation. The mean Hemoglobin percentage 9.6 gm% with standard deviation (±1.43) range 6.8 to 13 gm%, TLC 9372(±1157) K range 6K to 11K, TPC 186 (+18) Lakhs range 165 to 240 L, Serum Ferritin 737.8 (±772.6) ng range 23.9 to 3349 ng, MCV fl 62.11(±2.11) range 58.9 to 67 fl, MCH pg 19.02 (±2.07) range 14.8 to 22.4fl, MCHC 26.91(±1.42) range 23 to 29.8g% were observed in the present study. The Electrophoresis data of HbA%, HbF%, Hba2% and HbS% were seen as 2.27(±0.7) % range 1.4 to 4.4%, 19.8(±8.7) % range 7.2 to 45.4%, 3.4(±1.71) % range 1.3 to 7.8% and 72.8(±8.03) % range 53.6 to 83.2% respectively.

Table No 5: Sickle Beta Thalassemia(n=45) Mean value of hematological indices. S/E : standard error

|                          | Mean  | S/D  | P Value | S/E |
|--------------------------|-------|------|---------|-----|
| **Age yrs**              | 17.16 | 8.7  |<0.0001 | 1.3 |
| **Height**               | 134.44| 34.67|<0.0001 | 5.168|
| **Weight**               | 38.48 | 16.00|<0.0001 | 2.385|
| **Hb%**                  | 10.2  | ±1.9 |<0.0001 | 0.283|
| **TLC K**                | 9815  | 1649.6|<0.0001| 245.9|
| **TPC L**                | 184.3 L| 20.76|<0.0001| 3.095|
| **FERRITIN**             | 297.94| 99.62|<0.0001| 27.630|
| **MCV fl**               | 63.06 | 2.63 |<0.0001| 0.392|
| **MCH pg**               | 19.35 | 2.16 |<0.0001| 0.322|
| **MCHC**                 | 27.14 | 1.73 |<0.0001| 0.258|
| **HbA%**                 | 3.69  | 2.94 |<0.0001| 0.438|
| **HbF%**                 | 21.63 | 5.24 |<0.0001| 0.781|
| **HbA2%**                | 4.12  | 1.00 |<0.0001| 0.194|
| **HbS%**                 | 69.45 | 4.35 |<0.0001| 0.648|

Table No 5: The mean height in centimeters was 134.44 cms (± 34.67) range 73 to 176 centimeters and weight in kilograms is 38.48 kg (±16.00) range 16 to 80 kilograms which indicates growth retardation. All the 45 cases are sickling positive with mean haemoglobin percentage is 10.2(SD
(±1.9) with minimum 4.6gm% to maximum 13.6 gm%, the mean of TLC and TPC is 9815 (SD±1649.6) ranges from 6000 to 12300 & 184.3 lakhs (SD± 20.76) ranges from 162 to 245 L respectively. We measured serum ferritin in 13 cases and the mean is 297.94 ng/ml (SD±99.62) ranges from 116.3 to 434ng. Analysis of electrophoresis shows the mean value of HbA is 3.69(SD± 2.94) ranges from 1to 27.9 ,HbF 21.63 (SD± 5.24) ranges from 11 to 22.7 ,HbA2 4.12 (SD±1.00) ranges from 1.6 to 5.7 and HbS 69.45 (SD±4.35) ranges from 45.9 to 82.3. In our observation the fetal hemoglobin was raised to 21.63, ranging from 11% to 32.7% and Hb A2 was also raised with mean value 4.12 which is >3.5%, suggestive of sickle cell-β-thalassemia .We observed high percentage of HbS ranging from 45.9 to 82.3 the mean was being 69.45.Patients having high levels HbA2 (>3.5%) as well as HbS (67%) are determinant for Sickle cell beta thalassemia (Weatherall).(2)

The mean haemoglobin concentration of both the cases is 10.2 gm% SD ± 1.9 and 9.64±1.34 which shows moderate anaemia in our observation and similar to the study done by Maria Stella Figueiredo et.al 2015. Results were statistically analysed and tested using student’s t-test for significance, if any, between the different diagnostic groups. Since there was no statistically significant sex differences observed for different haematological indices in the studied diagnostic categories, their mean values were pooled together for comparison purposes (Table No 6). Statistically significant higher mean values were observed in sickle beta thalassemia patients i.e. HbA mean 3.69±2.94 P value <0.0027, HbA2 mean 4.12 P value <0.017 than in the sickle cell Disease. The mean height 145.69±31.08 P value <0.001, serum ferritin level 737.8±772.6 P value <0.0003 and HbS levels 72.8±8.03 P value <0.01 in Sickle Cell Disease were significantly higher in Sickle Cell Disease in comparison with Sickle Beta Thalassemia.

| Table No. 6: Mean value of hematological indices in Sickle Cell Phenotypes Odisha. |
|-----------------|------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Disease         | Sickle Cell Disease (n=43)   | Sickle Beta Thalassemia(n=45) |          |          |          |          |
|                 | Mean | S/D | S/E | P.Value | Mean | S/D | S/E |          |          |          |          |
| Age yrs         | 20.14 | 13.16 | 2.0 | 0.2116 | 17.16 | 8.7 | 1.3 |          |          |          |          |
| Height          | 145.69 | 31.08 | 4.74 | 0.001 | 134.44 | 34.67 | 5.168 |          |          |          |          |
| Weight          | 42.14 | 14.22 | 2.17 | 0.26 | 38.48 | 16.00 | 2.385 |          |          |          |          |
| Hb%             | 9.64 | 1.43 | 0.22 | 0.123 | 10.2 | ±1 | 0.283 |          |          |          |          |
| TLC K           | 9372.1 | 1157.3 | 240.5 | 0.15 | 9815 | 1649.6 | 245.9 |          |          |          |          |
| TPC L           | 186.11 | 17.78 | 2.7 | 0.66 | 184.3 L | 20.76 | 3.095 |          |          |          |          |
| FERRITIN        | 737.8 | 772.6 | 117.8 | 0.0003 | 297.94 | 99.62 | 27.630 |          |          |          |          |
| MCV fl          | 62.11 | 2.11 | 0.322 | 0.658 | 53.06 | 2.63 | 0.392 |          |          |          |          |
| MCH pg          | 19.02 | 2.07 | 0.316 | 0.99 | 19.35 | 2.16 | 0.322 |          |          |          |          |
| MCHC            | 26.91 | 1.42 | 0.217 | 0.49 | 27.14 | 1.73 | 0.258 |          |          |          |          |
| HbA%            | 2.27 | 0.7 | 0.122 | 0.0027 | 3.69 | 2.94 | 0.438 |          |          |          |          |
| HbF%            | 19.8 | 8.7 | 1.33 | 0.232 | 21.63 | 5.24 | 0.781 |          |          |          |          |
| HbA2%           | 3.40 | 1.71 | 0.261 | 0.017 | 4.12 | 1.00 | 0.194 |          |          |          |          |
| HbS%            | 72.8 | 8.03 | 1.23 | 0.01 | 69.45 | 4.35 | 0.648 |          |          |          |          |

| Table No. 7: After Hydroxyurea treatment. |
|-----------------|------------------------------|-----------------|-----------------|-----------------|-----------------|
| Observation      | Before Hydroxyurea Treatment | After Hydroxyurea Treatment |          |          |          |          |
|                  | SCD | SB+T | SCD | SB+T |          |          |
| HbF%             | 19.8±8.7 | 21.63±5.24 | 29.33±4.56 | 33.99±6.81 |          |          |
| B.T.Requird      | 14.45±1.84 | 5.44±1.97 | 4.76±2.34 | 2.58±2.09 |          |          |
| R- VOC           | 29 | 14 | 3 cases | 2 cases |          |          |
Table No. 7: Hydroxyurea was administered orally at doses between 10 and 20 mg/kg per day. There were overall increases in HbF in most of the cases with reductions in the frequency of VOC & AVN. There was marked reduction in requirement of blood transfusion from $14.45 \pm 1.84$ units’ to $4.76\pm2.34$ units in SCD and $5.44\pm1.97$ to $2.58 \pm 2.09$ in SBT. There was statistically significant increase in HbF from $19.8\pm8.7$ to $29.33 \pm 5.03$ (P value <0.0001) in SCD and from $21.63 \pm 5.24$ to $33.99\pm6.81$ (P Value< 0.0001) in SBT. Vasoocclusive crisis was also reduced from 29 to 03 and 14 to 02 before and after Hydroxyurea treatment in both the groups respectively. The overall incidence of avascular necrosis was reduced to normal in the present study.

Discussion
The present study shows that maximum 41 cases (91%) has been seen below 30 years of age in Sickle beta Thalassemia and 37(86%) in Sickle Cell Disease. Male patients are more than female which may be due to the fact that male child gets more attention as compared to female child. The median age is being 17 years in sickle beta thalassemia and 18 years in Sickle Cell Disease. The mean age and standard deviation is being $17.16\pm 8.7$ and $20.14\pm13.16$ in both the observed groups. The P value (<0.2), which is statically insignificant. The persistence of splenomegaly is higher in the present study probably due to the raised HbF level found in Indians. In general examination hepatosplenomegally, low grade fever and bone pain are invariably present. Recurrent blood transfusion is required in 22 cases ($14.45\pm 1.84$) in sickle cell disease and 18 cases ($5.44\pm1.97$) in Sβ+ Thalassemia having P value< 0.001 which is statistically very significant. Avascular necrosis, Hypertension and Cholelithiasis are insignificant association in our study. In Sickle Cell Disease (Table No 4) we observed growth retardation, anaemia, leucocytosis, increased Serum Ferritin and decreased levels of MCV, MCH and MCHC. The Electrophoresis data showed normal level of HbA% and increased level of HbF%, HbA2% and HbS% In sickle beta thalassemia (Table No 5) we observed the decrease of mean height and weight compared with the disabled world, which indicates growth retardation. All the 45 cases are sickling positive with mild anaemia, leucocytosis, increased Serum Ferritin and decreased levels of MCV, MCH and MCHC. In our observation the mean fetal hemoglobin is raised to 21.63 and Hb A2 to 4.12%, which is >3.5%, and high percentage of Hbs range (45.9 to 82.3) the mean is being 69.45 suggestive of sickle cell-beta-thalassemia. We compared Sickle Cell Disease with Sickle β+ Thalassemia in (Table No 6). The mean haemoglobin concentration of both the groups shows moderate anaemia. Statistically significant higher mean values of HbA, HbA2 are observed in sickle beta thalassemia than in the sickle cell Disease. The mean height, serum ferritin and HbS levels in are significantly higher in Sickle Cell Disease than Sickle Beta Thalassemia. It is apparent from (Table No 6) that the majority of the Sickle Cell Disease and sickle cell-β -thalassemia cases showed reduced values of red cell indices like MCV, MCH and MCHC suggestive of hypochromic and microcytic anaemia. Following Hydroxyurea treatment, there are overall increases in HbF in most of the cases with reductions in the frequency of vasoocclusive crisis & avascular necrosis as hydroxyurea increases the red cells containing an increased amount of fetal hemoglobin, which inhibits HbS polymerization, and decrease of leukocytes and platelets, which significantly limits their adherence to the vascular wall. There are marked reduction in requirement of blood transfusion due to increase in HbF level.

Conclusion
The high prevalence of sickle cell disease and beta thalassaemia in state of Odisha, India culminates the sickle beta thalassemia as major health
Difficult problem and has considerable morbidity and mortality. Differentiation of sickle cell anaemia and the sickle beta thalassemia syndromes has to be done carefully due to close similarity of symptoms and laboratory findings. The Hemoglobin Electrophoresis pattern of the Sickle Cell Disease and sickle-beta+ thalassemia consists of high HbS with a mild increase in HbF and HbA2 and low HbA value. Statistically significant higher mean values of HbA, HbA2 are observed in sickle beta thalassemia patients. Molecular diagnosis of Hb D, HbE or Hb S gene is required along with characterization of \( \beta \)-thalassemia mutations in this region. The prenatal diagnostic facilities, genetic/marriage counseling are the ultimate aims to be achieved in the state of Orissa.

References

1. Silverstroni E, Bicano,Granziani B, Carboni C. Heterozygous beta-thalassaemia with normal haemoglobin pattern. Haematologic, haemoglobin and biosynthesis study of 4 families. Acta Haematol 1978: 59(6):332-40.
2. Weatherall DJ, Clegg JB. The Thalassemia Syndromes. 4th ed. Oxford: Blackwell Scientific Publications; 2001.
3. Kinney T.R, Ware R.E, Embury S.H., Hebbel R.P., Mohandas and N.Steinberg M.H. Compound heterozygous states In Sickle cell disease. Basic principles and clinical practice. 1st ed. Raven Press Ltd.: New York: 1994. pp. 437–451.
4. Fabia Neves,Osvaldo Alves Menezes Neto,Larissa Bueno Polis,Sarah Cristina Bassi,Denise Menezes Brunetta,Ana Cristina Silva-Pinto and Ivan Lucena Angulo. Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment, Hematol Hemoter. 2012:34(6):426-9
5. Balgir R S. Aberrant Heterosis In Hemoglobinopathies With Special Reference To Thalassemia And Structurally Abnormal Hemoglobins E And S In Orissa, India. Journal of Clinical and Diagnostic Research: 2007 vol: 3:122-130.
6. Dacie J. 3rd ed. Churchill Livingstone :New York: 1988. The hereditary haemolytic anaemias.
7. Kinney T.R., Ware R.E. Compound heterozygous states of Sickle cell disease: basic principles and clinical practice. 1st ed. Raven Press Ltd.: New York: 1994. pp. 437–451.
8. Dr C. E. Omoti . Haematological Values In Sickle Cell Anaemia In Steady State And During Vaso-Occlusive Crisis In Benin City, Nigeria Annals of African Medicine: Vol: 4; No. 2: 2005: 62 – 67
9. Saurav Banerjee , Rabindra Kumar Singh, Ramesh Kumar Shrivastava, Sunil Kumar Mahto: Study Of Haemoglobinopathies In Patients Of Anaemia Using High Performance Liquid Chromatography (HPLC) J. Evolution Med. Dent. Sci. Vol: 05/ Issue 46/ June 09:2016: 3029 -3033.
10. Sanjeev Shyam Rao, Jagdish Prasad Goyal, S.V. Raghunath, Vijay B. Shah. Hematological profile of sickle cell disease from South Gujarat India. Hematology Reports 2012: volume 4:e8:22-23
11. Douglas R .Higgs M. B, Beverley E, Aldridge and Weatherall M.D. The Interaction of Alpha Thalassemia and Sickle Cell disease. N Engl J Med 1082: 306:1441-1446
12. Obeagu Emmanuel Ifeanyi. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria Int.J.Curr.Microbiol.App.Sci. 2014: 3(3): 1000-1005
13. Shailesh M Patel Electrophoresis Pattern In Clinically And Hematologically Suspected Cases Of Haemoglobinopathies. NJIRM 2012:Vol. 3(3):July –August :24-27
14. Maria Stella Figueiredo. The compound state: Hb S/beta-thalassemia 2015 May-Jun: 37(3): 150–152.

15. Eman A. Ajjack, Hiba A. Awooda, Sana Eltahir Abdalla. Haemoglobin Patterns in Patients with Sickle Cell Haemoglobinopathies, International Journal of Hematological Disorders. 2014: Vol. 1:No. 1: pp.8-11

16. Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Blood Cells Mol Disease 2000: 26(5):453-56

17. Rigano P, Rodgers GP, Renda D, Renda MC, Aquino A, Maggio A. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. Haemoglobin 2001: 25(1):9-17